UK Markets close in 2 hrs 53 mins

Allarity Therapeutics A/S (ALLR.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
1.9380+0.3190 (+19.70%)
As of 2:37PM CEST. Market open.
Full screen
Previous close1.6190
Open1.3490
Bid1.6000 x N/A
Ask1.6010 x N/A
Day's range1.5520 - 2.0000
52-week range0.6134 - 2.1475
Volume64,727,597
Avg. volume5,720,981
Market cap468.574M
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

    Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program Press release Hørsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) – Allarity Therapeutics A/S (“Allarity”) and Lantern Pharma Inc. (“Lantern”) today announced that they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (“LP-100”) and assume full authority to manage and guide future clini

  • Globe Newswire

    Allarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021

    Issuance of share Units fullfils payment obligations to guarantors and coordinator/bookrunner of Rights Issue conducted in Q2 2021 Press release Hørsholm, Denmark (14 July 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced a payment-in-kind and a debt conversion structured as a directed issue of 24,112,523 new share Units to the guarantors and to the global coordinator and bookrunner, Aalto Capital AB, of the rights issue completed on 11 June 2021 (the “Rights Issue”).

  • Globe Newswire

    Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP®

    Administrative acceptance review notification of pre-market approval (PMA) application is first step in multi-step process conducted by the FDAThe PMA is submitted in support of an imminent new drug application (NDA) for dovitinib Press release Hørsholm, Denmark (5 July 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has provided a positive administrative acceptance and review notification for the Company's PMA appl